Denali Therapeutics (DNLI) Non-Current Deffered Revenue (2018 - 2022)

Denali Therapeutics (DNLI) has 5 years of Non-Current Deffered Revenue data on file, last reported at $479000.0 in Q4 2022.

• On a quarterly basis, Non-Current Deffered Revenue fell 85.9% year-over-year to $479000.0 in Q4 2022; TTM through Dec 2022 was $479000.0, a 85.9% decrease from a year earlier, with the FY2022 full-year figure at $479000.0, down 85.9% from the prior year.
• Non-Current Deffered Revenue for Q4 2022 stood at $479000.0, down from $3.4 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for DNLI reached as high as $51.5 million in Q1 2018 and fell as low as $479000.0 in Q4 2022.
• Historically, Non-Current Deffered Revenue has averaged $24.4 million across 5 years, with a median of $24.5 million in 2018.
• Across the five-year window, Non-Current Deffered Revenue surged 4230.71% in 2019 and tumbled 89.15% in 2022, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $24.5 million in 2018, then soared by 78.35% to $43.8 million in 2019, then tumbled by 46.69% to $23.3 million in 2020, then tumbled by 85.43% to $3.4 million in 2021, then plunged by 85.9% to $479000.0 in 2022.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $479000.0 in Q4 2022, $3.4 million in Q2 2022, and $3.4 million in Q1 2022.